Overview
Stem cell and cell-based therapy is not one procedure. Products may contain hematopoietic stem cells, stromal or progenitor cells, immune cells, mixed bone-marrow cells, adipose-derived stromal vascular fraction, cultured cells, or donor tissue components. Source and processing determine identity and risk.
What FDA has approved
FDA states that the stem-cell products approved in the United States consist of blood-forming stem cells derived from umbilical cord blood for disorders affecting blood production. These are not approved for osteoarthritis, tendonitis, disc disease, chronic pain, neurologic disease, heart or lung disease, fatigue, autism, or anti-aging.
Common clinic labels can be misleading
- BMAC: a mixed autologous bone-marrow concentrate, not a purified or expanded stem-cell dose.
- Adipose/SVF: cells derived from fat with processing and regulatory status that must be evaluated specifically.
- Umbilical cord or Wharton’s jelly: donor-derived products do not automatically contain living stem cells at treatment and are not approved orthopedic cures.
- Amniotic products: composition, viability, intended use, and regulatory status vary; “birth tissue” is not proof of a stem-cell drug.
Autologous and same-day are not exemptions
A product made from a patient’s own tissue can still be regulated and can still cause harm. Processing, manipulation, homologous use, combination with other substances, route, and intended claims all matter. A clinic’s claim that it is “FDA registered” does not mean the treatment is FDA-approved.
Evidence and clinical trials
Preclinical mechanisms and small uncontrolled studies do not establish regeneration or disease modification. A legitimate clinical trial should have an IND when required, independent ethics review, protocol, monitoring, consent, registration, and a sponsor—not merely a paid listing on ClinicalTrials.gov.
Benefits
FDA-approved hematopoietic stem-cell products treat specific blood-system disorders
Cell therapies are an active area of legitimate clinical research
Autologous marrow procedures can be studied for defined orthopedic indications
Product-specific characterization can make risks and evidence assessable
Proper trials can evaluate dose, manufacturing, safety, and patient-important outcomes
The Procedure
1
Identify the exact product
2
Verify authorization
3
Screen patient and source risks
4
Administer with traceability
5
Long-term follow-up
Preparation
Request the product label, manufacturer, lot, source, processing, viability and dose data, FDA approval or IND documentation, trial consent, facility credentials, and adverse-event plan. Bring imaging, diagnoses, cancer and infection history, medications, and prior biologic treatments.
Recovery & Aftercare
Recovery depends on harvest and administration. Marrow or fat collection adds donor-site pain, bleeding, anesthesia, and infection risk. Injected, intravenous, spinal, ocular, or inhaled routes have different hazards and follow-up needs.
Risks & Considerations
Infection, contamination, bleeding, anesthesia complications, immune reactions, clots or emboli, neurologic or vascular injury, blindness, abnormal tissue or tumor formation, product misidentification, disease transmission, treatment failure, and delayed effective care. Autologous origin does not remove these risks.
Frequently Asked Questions
References
[1]
FDA Consumer Alert: Regenerative Medicine Products Including Stem Cells and Exosomes.
https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes[2]
FDA. Important Patient and Consumer Information About Regenerative Medicine Therapies.
https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies[3]
FDA. Cellular and Gene Therapy Products.
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products
Your Privacy Choices